Business Insider

Recludix Pharma to Present Data Demonstrating its Oral STAT3 Inhibitor has Differentiated Efficacy and Safety as Compared to JAK/TYK2 Inhibition in In Vivo Models of ...

-REX-7117 is an oral, potent and selective STAT3 SH2 domain inhibitor, which demonstrated strong efficacy in an in vivo model of inflammatory arthritis -STAT3 inhibition does not impair the interferon ...

Tvardi Therapeutics Announces Further Phase 2 REVERT IPF Data, Expanding Clinical Insights

Pooled patients treated with TTI-101 demonstrated a 9.4% decrease from baseline in fibrosis score at week 12, compared to a 2 ...
Nasdaq

Moleculin Announces First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of Glioblastoma

HOUSTON, Sept. 9, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company), a Phase 3 clinical-stage pharmaceutical company with a broad portfolio of drug candidates ...
BioWorld

STAT3 inhibitors disclosed in Altay Therapeutics patent

Altay Therapeutics Inc. has divulged signal transducer and activator of transcription 3 (STAT3) inhibitors reported to be useful for the treatment of cancer, autoimmune disease, diabetes, inflammatory ...
JSTOR Daily

Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts

Computer-aided lead optimization derives a unique, orally bioavailable inhibitor of the signal transducer and activator of transcription (Stat)3 Src homology 2 domain. BP-1-102 binds Stat3 with an ...
EurekAlert!

Schematic diagram of the IL-6/JAK/STAT3 signaling pathway activation in mouse liver macrophages. (IMAGE)

Schematic diagram of the IL-6/JAK/STAT3 signaling pathway activation in mouse liver macrophages. IRs, inhibitory receptors (IRs); ICIs, immune checkpoint inhibitors; IL-6, interleukin-6; ALT, alanine ...